Several distinct congenital disorders can lead to tissue-iron overload with anemia. Repeated blood transfusions are one of the major causes of iron overload in several of these disorders, including β-thalassemia major, which is characterized by a defective β-globin gene. In this state, hyperabsorption of iron is also observed and can significantly contribute to iron overload. In β-thalassemia intermedia, which does not require blood transfusion for survival, hyperabsorption of iron is the leading cause of iron overload. The mechanism of increased iron absorption in β-thalassemia is unclear. We definitively demonstrate, using genetic mouse models, that intestinal hypoxia-inducible factor-2α (HIF2α) and divalent metal transporter-1 (DMT1) are activated early in the pathogenesis of β-thalassemia and are essential for excess iron accumulation in mouse models of β-thalassemia. Moreover, thalassemic mice with established iron overload had significant improvement in tissue-iron levels and anemia following disruption of intestinal HIF2α. In addition to repeated blood transfusions and increased iron absorption, chronic hemolysis is the major cause of tissue-iron accumulation in anemic iron-overload disorders caused by hemolytic anemia. Mechanistic studies in a hemolytic anemia mouse model demonstrated that loss of intestinal HIF2α/DMT1 signaling led to decreased tissue-iron accumulation in the liver without worsening the anemia. These data demonstrate that dysregulation of intestinal hypoxia and HIF2α signaling is critical for progressive iron overload in β-thalassemia and may be a novel therapeutic target in several anemic iron-overload disorders.
Several distinct congenital disorders can lead to tissue-iron overload with anemia. Repeated blood transfusions are one of the major causes of iron overload in several of these disorders, including β-thalassemia major, which is characterized by a defective β-globin gene. In this state, hyperabsorption of iron is also observed and can significantly contribute to iron overload. In β-thalassemia intermedia, which does not require blood transfusion for survival, hyperabsorption of iron is the leading cause of iron overload. The mechanism of increased iron absorption in β-thalassemia is unclear. We definitively demonstrate, using genetic mouse models, that intestinal hypoxia-inducible factor-2α (HIF2α) and divalent metal transporter-1 (DMT1) are activated early in the pathogenesis of β-thalassemia and are essential for excess iron accumulation in mouse models of β-thalassemia. Moreover, thalassemic mice with established iron overload had significant improvement in tissue-iron levels and anemia following disruption of intestinal HIF2α. In addition to repeated blood transfusions and increased iron absorption, chronic hemolysis is the major cause of tissue-iron accumulation in anemic iron-overload disorders caused by hemolytic anemia. Mechanistic studies in a hemolytic anemia mouse model demonstrated that loss of intestinal HIF2α/DMT1 signaling led to decreased tissue-iron accumulation in the liver without worsening the anemia. These data demonstrate that dysregulation of intestinal hypoxia and HIF2α signaling is critical for progressive iron overload in β-thalassemia and may be a novel therapeutic target in several anemic iron-overload disorders.
thalassemia | HIF | Epas1 | Slc11a2 S econdary hemochromatosis is a group of distinct diseases that lead to iron accumulation, and several diseases within this group also have concomitant anemia (www.irondisorders.org). These disorders are very problematic to treat because phlebotomy, which is a very effective treatment for iron overload, is not an option due to the anemia. In many cases, diseases of iron overload with anemia are treated with a combination of erythropoietic stimulators, blood transfusions, and/or iron chelators (1). Increased iron loading in secondary hemochromatosis, particularly in the liver, is associated with increased morbidity and mortality (2). Because the main cause of death in β-thalassemia is iron overload (3), a major focus is to investigate the mechanisms involved in iron accumulation. Three major mechanisms have been attributed to the tissue-iron accumulation associated with several different anemic iron-overload diseases: (i) repeated blood transfusions, (ii) increased iron absorption, and (iii) chronic hemolysis. In conditions of severe anemia, such as β-thalassemia major, which is due to loss of functional β-globin protein, these patients have profound anemia as well as complications due to the production of abnormal red cells, requiring regular blood transfusions for survival. The transfused blood contains a significant amount of iron, which can lead to iron overload. Interestingly, patients with β-thalassemia due to partial loss of the β-globin gene product do not require blood transfusions for survival but exhibit iron overload (4, 5) . This condition has been defined as β-thalassemia intermedia or nontransfusion-dependent thalassemia, and the mechanisms that contribute to iron overload are unclear (6) . In addition, in diseases such as hemolytic and sideroblastic anemia the iron overload is due to chronic hemolysis. Through a mechanism similar to transfusions, increased hemolysis releases large of amounts of iron from red blood cells, which accumulates in tissues.
The liver is a central sensor and regulator of iron homeostasis, which is controlled through the expression of the hepatic hormone hepcidin. Hepcidin is a small peptide produced in the liver and secreted into the bloodstream that controls systemic iron homeostasis (7, 8) . Hepcidin acts by binding to ferroportin (FPN1, also known as SLC40A1) (9) (10) (11) (12) , the only known mammalian iron exporter, which leads to its internalization and degradation (13) . FPN1 is primarily expressed on enterocytes and macrophages of the reticuloendothelial system; thus, hepcidin acts to limit both duodenal iron absorption and release of iron from stores (14, 15) . Hepcidin expression is decreased in several disorders of secondary hemochromatosis (16, 17) . Multiple mechanisms control hepcidin expression in β-thalassemia (18) , including the erythropoietic-induced repressors of hepcidin,
Significance
Several distinct congenital disorders can lead to tissue-iron overload with anemia. Tissue-iron accumulation is the major cause of mortality in these patients. Intestinal hypoxia-inducible factor-2α (HIF2α) and its downstream target gene divalent metal transporter-1 (DMT1) are essential for iron absorption during times of increased iron demand. However, the role of the intestinal HIF2α/DMT1 signaling axis in iron overload disorders has not been assessed. We demonstrate that HIF2α and DMT1 in the small intestine are highly activated early in mouse models of anemic iron overload and that disruption of their expression can prevent and improve tissue-iron accumulation in these disorders. These results demonstrate that HIF2α and DMT1 are ideal therapeutic targets in ironoverload disorders.
growth differentiation factor-15 (GDF15) and twisted gastrulation (TWSG1) (19, 20) . GDF15 and TWSG1 are secreted by erythropoietic precursors under conditions of erythropoietic stress and inhibit hepcidin expression. The prevailing thought is that the decrease in liver hepcidin is a critical factor in the hyperabsorption of iron. Increasing hepcidin levels inhibits iron overload in mouse models of β-thalassemia (21) (22) (23) . Moreover, modulation of hepcidin levels can mobilize iron, suggesting that changes in hepcidin could be beneficial in several disorders that lead to iron overload with anemia that are not caused by hyperabsorption of iron. However, treatment with hepcidin does not completely correct serum and tissue-iron levels in ironoverload disorders with anemia (21) (22) (23) .
The intestine is also a critical sensor and regulator of systemic iron homeostasis. Intestinal oxygen sensing is essential for adaptive increases in iron absorption. Intestinal hypoxia-inducible factor 2 alpha (HIF2α) is a critical regulator of iron absorption in the settings of iron deficiency, erythropoiesis, and hepcidin deficiency (24) (25) (26) (27) (28) (29) . HIF2α is a member of the family of hypoxia-inducible transcription factors, which control the cellular and systemic response to oxygen deficiency (30) . The apical ferric reductase, duodenal cytochrome B [DcytB (31) (32) (33) ] and the apical iron transporter, divalent metal transporter 1 (DMT1, also known as SLC11A2) (31, 34, 35) , and the basolateral iron exporter FPN1 are direct HIF2α target genes (25, 26, 29) . Despite the critical role of these apical transporters in iron absorption, no studies have examined the expression of these genes in β-thalassemia in mechanistic detail. Moreover, very little has been done to examine the integral role of local intestinal iron sensing and regulation in other anemic iron-overload disorders.
In this study, an intestinal hypoxia-HIF2α-DMT1 signaling axis was shown to be critical in the iron overload associated with β-thalassemia and hemolytic anemia. In addition, blocking intestinal HIF2α in mice with established iron overload led to a decrease in tissue iron while improving the anemia, providing a unique therapeutic target for patients with anemic iron-overload disorders. ) was developed that recapitulates the human phenotype (36) (37) (38) . These mice have a heterozygous deletion in the β-minor and β-major chain of hemoglobin. Hbb th3/+ mice develop severe anemia as well as progressive iron overload in the absence of blood transfusions, demonstrating that increased iron absorption plays a critical role in the disease pathogenesis. The mechanism of increased iron absorption is unclear and has not been targeted therapeutically in humans (39) . One-month-old Hbb th3/+ mice have a significant increase in liver iron compared with wild-type littermate Hbb +/+ mice as determined by iron staining (Fig. 1A) and tissue nonheme iron quantitation (Fig. 1B) . Consistent with previous reports, 3-wk-old Hbb th3/+ mice had lower liver hepcidin expression compared with littermate controls Hbb +/+ (Fig. 1C ) (16) . No change in duodenal FPN1 protein expression was observed (Fig. 1D ). Robust and significant increases in DMT1 and DcytB were observed in 3-wkold Hbb th3/+ mice (Fig. 1D) . Gene expression analysis demonstrated a significant increase in DMT1 and DcytB but no change in FPN1 in Hbb th3/+ mice compared with littermate controls (Fig.  1E ). These data demonstrate that mechanisms in addition to the hepcidin/FPN1 axis are critical for iron overload in β-thalassemia.
β-Thalassemic Mice Exhibit Systemic and Duodenal Hypoxia. Intestinal DMT1 and DcytB were increased early in the pathogenesis of tissue-iron accumulation in a mouse model of β-thalassemia. These genes are direct hypoxia and HIF2α target genes (26) . To determine whether mice with β-thalassemia are hypoxic, the hypoxia reporter mouse, ODD-luc, was crossed with the Hbb th3/+ mice (40) . In vivo luminescence imaging of mice from this cross demonstrated that 3-wk-old thalassemic mice are systemically hypoxic ( Fig. 2A) . The increase in luminescence is evident in the abdomen and peripheral areas, such as the paws and tails. To obtain better resolution, tissues were excised and luciferase activity was measured. A significant increase in luciferase activity was observed in the liver, small intestine, and kidney (Fig. 2B) . The increase in intestinal luminescence correlated to an increase in intestinal HIF2α and DMT1 expression, but not FPN1 (Fig.  2C) . The increase in small-intestinal hypoxia and HIF2α in the β-thalassemic model compared with wild-type littermates (Hbb +/+ ) suggests that the increased iron absorption in β-thalassemia could be due to intestinal hypoxia.
Increased Iron Absorption and Tissue-Iron Overload in Mouse Models
of β-Thalassemia Are Dependent on HIF2α. Bone marrow transplantation (BMT) of Hbb th3/+ bone marrow into irradiated wildtype syngeneic mice leads to stable ineffective erythropoiesis and iron overload, hallmarks of β-thalassemia (36) . This method provides a powerful and rapid means to assess genes critical in the disease progression of β-thalassemia. Intestinal HIF2α is a central transcription factor regulating iron absorption (25) (26) (27) 29) ; mice with the Hif2α gene floxed (Hif2α th3/+ and Hbb +/+ mice. DMT1 loading was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) whereas FPN1 and DcytB were normalized to coomassie staining, and the blots were quantitated and presented as fold changes compared with Hbb +/+ mice (Right). (E) qPCR analysis measuring intestinal Dmt1, Fpn1, and Dcytb gene expression. Expression was normalized to β-actin. Four to eight mice were assessed per each group, and each bar graph represents the mean value ± SD. *P < 0.01.
the role of intestinal HIF2α in thalassemic iron absorption, Hif2α ΔIE mice or littermate controls (Hif2α F/F ) were lethally irradiated and transplanted with Hbb th3/+ or Hbb +/+ bone marrow (Fig. 3A) . One month following BMT, expression of duodenal iron transporter genes was analyzed. The expression of the apical iron transporters Dmt1 and Dcytb was significantly increased in Hif2α F/F mice that were subjected to BMT from Hbb th3/+ donors (Fig. 3B ). To understand the mechanistic basis for the increase in Dmt1 and Dcytb, bone marrow from Hbb th3/+ mice was transplanted into Hif2α ΔIE mice. The increase in Dmt1 and Dcytb was completely abolished in the Hif2α ΔIE mice (Fig. 3B ). To understand whether the increase in apical iron absorption genes and intestinal HIF2α signaling is important in tissue-iron accumulation, liver iron was quantitated. As previously shown, Hif2α ΔIE mice on an iron-replete diet for 1 mo do not have any significant difference in liver iron compared with Hif2α F/F mice (Fig. 3C ). Irradiated Hif2α ΔIE mice transplanted with wild-type bone marrow (Hbb +/+ ) demonstrate a significant drop in liver iron compared with irradiated littermate controls transplanted with wild-type bone marrow (Fig. 3C ). This decrease may be due to the importance of intestinal HIF2α in iron absorption following erythropoiesis (27) . Hif2α F/F mice transplanted with Hbb th3/+ bone marrow demonstrated a significant increase in liver iron 1 mo following BMT, but the increase in liver iron was entirely ameliorated in the Hif2α ΔIE mice (Fig. 3C ). To confirm the role of the intestinal HIF2α response in thalassemic iron overload without the confounding effects of radiation, the Hif2α ΔIE and Hif2α F/F mice were crossed to the Hbb th3/+ mice. The increase in Dmt1 and Dcytb gene expression and protein expression that was observed in the BMT model of β-thalassemia was recapitulated in the 2-mo-old Hif2α (Fig. 4 A and B) . Additionally, no change in FPN1 was observed in 2-mo-old thalassemic mice (Fig. 4B) . When assessed for iron content by diaminobenzidine (DAB)-enhanced Perls' Prussian blue staining, Hif2α
F/F /Hbb th3/+ mice exhibited significantly higher accumulation of liver iron and spleen iron than wildtype littermates at 2 mo of age (Fig. 4C) . The staining in the liver was mainly localized to hepatocytes and is consistent with what is observed in β-thalassemic patients (41) . Disruption of intestinal HIF2α in the β-thalassemia model resulted in normalization of liver iron similar to the levels observed in wild-type mice (Fig. 4C ). Liver-iron quantitation confirmed that the increase in iron accumulation observed in the Hif2α (Fig. 4D) . No change in serum iron, but a significant decrease in hepcidin expression, was noted at this time point, suggesting that an increase in tissue iron can relieve systemic increases in iron, or that tissue iron is a more sensitive measure of iron overload (Figs. S1 and S2). Moreover, , and FPN1 expression. HIF2α expression was normalized to lamin B1, DMT1 expression was normalized to GAPDH, and FPN1 expression was normalized to coomassie staining, and the blots were quantitated and presented as fold changes compared with Hbb +/+ mice (Right). Three to five mice were assessed per each group, and each bar graph represents the mean value ± SD. *P < 0.01. F/F and Hif2α ΔIE mice were transplanted with Hbb +/+ or Hbb th3/+ bone marrow and analyzed 1 mo later for (B) intestinal Dmt1 and Dcytb mRNA expression and (C) liver iron content. mRNA expression was normalized to β-actin, and tissue-iron content was calculated per mg wet weight. Six to eight mice were assessed per each group, and each bar graph represents the mean value ± SD. *P < 0.01. the decrease in hepcidin expression was similar in the Hif2α ΔIE / Hbb th3/+ mice compared with Hif2α F/F /Hbb th3/+ mice, suggesting that the decrease in iron accumulation is independent of hepcidin signaling (Fig. S2) . Hematologic parameters were also assessed and demonstrated a slight but not statistically significant improvement compared with Hif2α F/F /Hbb th3/+ mice ( Fig. 4E and Fig. S3 ). Together, the data suggest that HIF-2α is critical in the pathogenesis of iron accumulation in β-thalassemia.
Temporal Deletion of Intestinal HIF2α Improves Iron Accumulation in
Thalassemic Mice with Established Iron Overload. Blocking intestinal HIF2α restricts iron absorption leading to a decrease in tissueiron accumulation. However, it is not clear whether existing iron that is accumulated in the liver can be cleared or mobilized more efficiently through inhibition of intestinal HIF2α and blocking of iron absorption. To answer this question, Hif2α
F/F mice were crossed with villin-Cre-ER T2 transgenic mice to generate a temporal and conditional disruption of Hif2α (Hif2α F/F;VilERcre ). The Cre is activated in intestinal epithelial cells only following tamoxifen administration, which leads to disruption of HIF2α. To confirm the inducibility, the Hif2α F/F;VilERcre mice were crossed to yellow fluorescent protein reporter (YFP) mice, in which Cre activation would be delineated by expression of YFP. Three 1.5-mg doses of tamoxifen led to efficient recombination in the small intestine and a robust decrease in intestinal HIF2α expression (Fig. S4) . To investigate the role of intestinal HIF2α in mice with established iron overload due to thalassemia, Hif2α F/F;VilERcre or littermate controls (Hif2α F/F ) were lethally irradiated and transplanted with Hbb th3/+ or Hbb +/+ bone marrow. Two months following BMT, mice were treated with vehicle or tamoxifen and killed at 4 mo following BMT (Fig. 5A) /Hbb th3/+ , and Hif2α ΔIE /Hbb th3/+ mice. Six to eight mice were assessed per each group, and each bar graph represents the mean value ± SD. *P < 0.01. For Western quantitation, the mean values ± SD are represented. *P < 0.01 compared with Hif2α cant difference in the expression of Dmt1, Dcytb, and Fpn1 4 mo following BMT (Fig. 5B) . Transplant of Hbb th3/+ bone marrow into Hif2α F/F and Hif2α F/F;VilERcre led to a significant increase in intestinal Dmt1 and Dcytb expression 2 mo following BMT. Interestingly, intestinal Fpn1 expression was also increased, confirming a previous study demonstrating that FPN1 expression is induced in aged thalassemic mice (Fig. 5B) (42) . Gene-expression analysis of the small intestine of 4-mo-old Hif2α F/F and Hif2α F/F;VilERcre mice transplanted with Hbb th3/+ bone marrow and treated with tamoxifen at 2 mo was performed. The data demonstrated that the increase in Dmt1, Dcytb, and Fpn1 was completely attenuated in tamoxifen-treated Hif2α F/F;VilERcre mice 4 mo after transplant (Fig. 5B) . Protein expression analysis was consistent with the gene-expression analysis in BMT of Hif2α F/F and Hif2α F/F;VilERcre mice (Fig. 5C ). Liver iron was assessed to determine whether HIF2α disruption improved iron accumulation. Transplant of Hbb +/+ bone marrow into Hif2α
and Hif2α ΔIE mice led to a significant decrease of liver iron in the Hif2α ΔIE mice 4 mo following BMT. These data suggest that as the mice age, intestinal HIF2α may play a more important role in basal iron absorption (Fig. 5D) F/F mice have a further increase in liver iron compared with when they are assessed at 2 mo. The Hif2α F/F;VilERcre mice treated with tamoxifen have a significant attenuation of liver iron (Fig. 5D) . Transplant of Hbb th3/+ bone marrow into Hif2α
F/F mice also demonstrated a significant increase in serum iron, which was completely attenuated in similarly treated Hif2α F/F;VilERcre mice at 4 mo (Fig. S5) . Assessment of liver hepcidin expression 4 mo after transplant demonstrated a decrease in hepcidin expression in all groups compared with Hif2α F/F mice receiving Hbb +/+ bone marrow. Hepcidin expression was not significantly different in mice, regardless of improvement in tissue-iron accumulation. (Fig. S6) . Furthermore, the disruption of HIF2α 4 mo following BMT of Hbb th3/+ marrow demonstrated a significant improvement in hematological parameters compared with similarly treated Hif2α F/F mice ( Fig. 5E and Fig. S7) . Together, the data demonstrate that intestinal HIF2α can be therapeutically targeted in anemic iron-overload disorders.
Loss of Intestinal HIF2α Decreases Iron Accumulation due to
Hemolysis. The observation that HIF2α inhibition could be beneficial in β-thalassemic mice with established iron overload suggests that HIF2α could be a useful target in several conditions that cause iron loading with anemia. In patients with hemolytic anemia, the tissue-iron accumulation is due to hemolysis. Phenylhydrazine (PhZ)-induced hemolysis is a well characterized model for hemolytic anemia that leads to an increase in liver iron that is poorly mobilized over time (43, 44) . In this model, intestinal iron absorption is important for erythropoietic recovery but is not required for iron accumulation (27) . This model is optimal to study the role of intestinal HIF2α in decreasing iron accumulation following hemolysis. Hif2α F/F mice were treated with PhZ, and liver iron was measured at 2 and 7 d after treatment. Hif2α F/F mice had a significant increase in liver iron 2 d after PhZ treatment, and levels remained high 1 wk following treatment (Fig. 6A) . Similar to wild-type mice, PhZ treatment of Hif2α ΔIE mice causes substantial liver iron loading 2 d following treatment. However, 7 d after PhZ treatment, liver-iron content decreased to normal levels in the Hif2α ΔIE mice (Fig. 6A) . Given that the initial iron loading at 2 d after PhZ was significantly lower in the Hif2α ΔIE mice compared with Hif2α F/F mice, the Hif2α F/F;VilERcre mice were also assessed. This model will allow similar hemolysis-induced iron loading and more accurate assessment of how fast iron can be mobilized and/or used from the liver following HIF2α disruption. Hif2α F/F and Hif2α F/F;VilERcre mice were treated with vehicle or PhZ, and liver iron was measured at 2 d after treatment or the mice were treated with tamoxifen and assessed for liver iron at 7 d following PhZ treatment (Fig. 6B, Inset) . There was no significant difference in the iron accumulation at 2 d following PhZ treatment in the Hif2α F/F and Hif2α F/F;VilERcre mice. Acute disruption of intestinal HIF2α led to a significant decrease in liver iron 7 d following PhZ administration whereas Hif2α F/F mice still had significant iron accumulation at 7 d following PhZ treatment. These data demonstrate that inhibition of intestinal HIF2α could be beneficial in anemic iron-overload disorders due to hemolysis.
Disruption of DMT1 Decreases Iron Accumulation in Mouse Models of
β-Thalassemia and Hemolytic Anemia. The data suggest that the apical proteins DMT1 and DcytB are critical downstream effectors of HIF2α in mouse models of anemic iron overload. The role of DMT1 in iron-overload disorders with anemia was assessed. Mouse models with a temporal disruption of DMT1 in intestinal epithelial cells were generated. Disruption of DMT1 in intestinal epithelial cells leads to a rapid and progressive anemia (11) . Therefore, a cross of Dmt1 F/+ mice to the villin-Cre-ERT2 mice was generated to disrupt one Dmt1 allele. This cross led to no significant difference in the basal Dmt1 expression in the small intestine 1 mo following tamoxifen treatment but dramatically decreased the low iron-induced expression of Dmt1 (Fig.  S8A) . There was no significant difference in serum iron on ironreplete or low-iron diet for 2 wk in tamoxifen-treated Dmt1 with Dmt1 F/+ mice following tamoxifen treatment ( Fig. S8 B and  C) . These data demonstrate that disrupting a single allele of Dmt1 in the intestine is an ideal model to understand the significance of intestinal DMT1 induction in β-thalassemia without the confounding systemic anemia that is associated with complete intestinal disruption. To understand the role of DMT1 in iron accumulation in β-thalassemia, Dmt1
F/+ and Dmt1 F/+;VilERcre were treated with tamoxifen, and irradiated mice were transplanted with Hbb th3/+ or Hbb +/+ bone marrow (Fig. 7A) . One month following BMT, DMT1 gene expression and protein expression were assessed. Deletion of one allele of Dmt1 did not affect basal DMT1 expression in Dmt1 F/+ and Dmt1 F/+;VilERcre mice transplanted with Hbb +/+ bone marrow ( Fig. 7 B and C) . A significant increase in intestinal Dmt1 expression was observed in Dmt1 F/+ transplanted with Hbb th3/+ bone marrow, which was significantly decreased in the Dmt1 F/+;VilERcre mice ( Fig. 7 B and C) . Consistent with these data, liver iron was not altered in the Dmt1 F/+ and Dmt1 F/+;VilERcre mice transplanted with Hbb +/+ bone marrow. No change in serum iron was observed (Fig. S9) ; however, an increase in liver iron accumulation was observed in Dmt1 F/+ mice transplanted with Hbb th3/+ bone marrow, which was significantly attenuated in the Dmt1 F/+;VilERcre mice (Fig. 7D) . A decrease in liver hepcidin expression was observed in Dmt1 F/+ and Dmt1 F/+;VilERcre mice transplanted with Hbb th3/+ bone marrow. These data suggest that disruption of DMT1 attenuates iron accumulation via a hepcidin-independent mechanism, similar to that observed following intestinal HIF2α disruption in the intestine (Fig. S10) . The role of Dmt1 was also assessed in iron accumulation following hemolysis.
Dmt1
F/+ and Dmt1 F/+;VilERcre mice were treated with vehicle or or phenylhydrazine (PhZ), and liver iron was quantitated 2 and 7 d following treatment. (B) Hif2α F/F and Hif2α F/F;VilERcre mice were treated with vehicle (Con) or phenylhydrazine (PhZ), and liver iron was quantitated or the mice were additionally treated with 1.5 mg of tamoxifen for 3 consecutive days, and liver iron was quantitated 7 d following PhZ treatment. Four to eight mice were assessed per each group, and each bar graph represents the mean value ± SD. NS, not significant; *P < 0.01; # P < 0.05.
PhZ, and liver iron was measured at 2 d after treatment or the mice were treated with tamoxifen and assessed for liver iron at 7 d following PhZ treatment (Fig. 7E, Inset) . There was no significant difference in the iron accumulation at 2 d following PhZ treatment in the Dmt1 F/+ and Dmt1 F/+VilERcre mice. However, following tamoxifen treatment, hemolysis-induced iron accumulation in the liver of Dmt1 F/+;VilERcre mice was significantly lower compared with tamoxifen-treated Dmt1 F/+ mice at 7 d following PhZ treatment (Fig. 7E) . These data suggest that DMT1 is an important downstream target gene of HIF2α that modulates iron accumulation in iron-overload disorders with anemia.
Discussion
Previous work has demonstrated an integral role of intestinal HIF2α signaling in iron absorption. HIF2α is a critical regulator of the apical iron absorption genes DMT1 and DcytB and the only known mammalian basolateral exporter FPN1. During increased systemic requirements for iron, intestinal HIF2α is highly activated, leading to an adaptive increase in iron absorption. Several studies have cemented the role of intestinal HIF2α in physiological regulation of iron homeostasis. However, the role of HIF2α signaling in the pathogenesis of iron-overload disorders was unclear. Recently, it was demonstrated that intestinal HIF2α signaling was essential for liver iron overload following hepcidin deficiency (28) . It is not clear the pathway by which HIF2α is activated during hepcidin deficiency. We hypothesized that intestinal HIF2α would be critical in iron accumulation in specific anemic iron-overload disorders such as β-thalassemia because it has been shown that anemia induces intestinal hypoxia (27) and that hyperabsorption of iron contributes significantly to the iron overload (4, 5) . Consistent with this hypothesis, HIF2α was activated early in the pathogenesis of iron accumulation in 
(E) Dmt1
F/+ and Dmt1 F/+;VilERcre mice were treated with vehicle (Con) or phenylhydrazine (PhZ), and liver iron was quantitated or the mice were additionally treated with 1.5 mg of tamoxifen for 3 consecutive days, and liver iron was quantitated 7 d following PhZ treatment. Six to eight mice were assessed per each group, and each bar graph represents the mean value ± SD. *P < 0.01, # P < 0.05. For Western quantitation, the mean values are represented. *P < 0.01 compared with Hbb th3/+ bone marrow transplanted into Dmt1 F/+ mice.
mouse models of β-thalassemia, and disruption of intestinal HIF2α corrected the iron overload. Moreover, a significant repression of hepcidin is observed in β-thalassemia; however, this decrease still persists in mice with a disruption of intestinal HIF2α. These data suggest that HIF2α and hepcidin operate independently or that HIF2α is downstream of hepcidin signaling to control iron overload in β-thalassemia. Recent studies based on HIF2α structural analysis have identified compounds that specifically inhibit HIF2α function and present the possibility of HIF2α-based therapeutics, although these compounds have not yet been demonstrated to have in vivo efficacy (45) (46) (47) . To determine whether HIF2α would be a good therapeutic target to decrease tissue-iron accumulation, a mouse model with a temporal disruption of intestinal HIF2α was used. The data clearly demonstrated that β-thalassemic mice with established iron overload significantly improved with respect to tissue-iron accumulation upon disruption of intestinal HIF2α. Moreover, limiting intestinal iron absorption improved the anemia associated with β-thalassemia. These data are consistent with previous reports demonstrating that decreased tissue-iron accumulation in β-thalassemia correlates to improvement in complete blood count (CBC) parameters (21) (22) (23) 48) . Currently the mechanism leading to a decrease in iron accumulation in β-thalassemic mice with established iron overload is not completely clear. Disruption of intestinal HIF2α may work through two mechanisms: (i) blocking iron absorption, therefore inhibiting further iron accumulation, (ii) or leading to more efficient iron mobilization and utilization from the liver. These data suggest that blocking HIF2α may be beneficial in other conditions that lead to iron-overload disorders with anemia. To test this possibility, a hemolytic anemia model was used. Iron accumulation in this model is directly due to increased hemolysis and independent of iron absorption. Disruption of HIF2α led to decreased iron accumulation following hemolysis, providing further rationale that intestinal HIF2α is a highly efficacious target for anemic iron-overload disorders.
Dmt1, Dcytb, and Fpn1 are all direct HIF2α target genes, but the increase in intestinal DMT1 and DcytB preceded changes in FPN1 in the small intestine of β-thalassemic mice. These results are consistent with the difference in kinetics observed in the regulation of these genes by HIF2α (25) . No significant change in FPN1 protein expression was observed until 2 mo following induction of β-thalassemia, and a further increase was observed at 4 mo. The increase in Fpn1 gene expression was completely dependent on HIF2α. The increase in protein expression was only partially dependent on intestinal HIF2α signaling. These findings are similar to FPN1 induction by chronic low-iron diet treatment, which is thought to be due to the regulation of FPN1 degradation by hepcidin. Indeed, hepcidin levels are decreased in mouse models of β-thalassemia and in thalassemic patients (17) . Restoring hepcidin levels can improve iron accumulation in β-thalassemic mice, demonstrating the importance of hepcidin in anemic iron-overload disorders (21) (22) (23) . However, the rapid increase in HIF2α, DMT1, and DcytB indicates the importance of the apical iron transport proteins early in the pathogenesis of iron accumulation in mouse models of β-thalassemia. To test this possibility, a mouse model was generated in which a single allele of Dmt1 was disrupted specifically in the intestine. The mice on a normal diet were indistinguishable from their wild-type littermates. However, the induction of Dmt1 that is observed in the intestine following low-iron diet or in thalassemic mice is significantly attenuated in mice disrupted for a single allele of Dmt1 in the intestine. These mice had decreased iron accumulation in mouse models of β-thalassemia and hemolytic anemia. These results demonstrate the importance of DMT1 in iron-overload disorders and provides good rationale to target DMT1 in anemic iron-overload disorders. Similar to HIF2α, compounds have been identified that inhibit DMT1 function (49, 50) , and thus it may be possible to specifically inhibit DMT1 as a novel treatment modality in iron-overload disorders.
In summary, the present study demonstrates that the intestine, liver, and kidney as observed in the hypoxia reporter mice are the major susceptible tissues to systemic changes in oxygen delivery. This sensitivity may be due to their critical role in erythropoiesis and systemic iron homeostasis. In the pathogenesis of anemic iron-overload diseases such as β-thalassemia, intestinal hypoxia leads to activation of HIF2α, which increases DMT1 expression, contributing to tissue-iron accumulation. Inhibition of HIF2α or DMT1 prevents tissue iron loading in β-thalassemia. Moreover, inhibition of HIF2α or DMT1 can decrease tissue-iron accumulation in mouse models of β-thalassemia and hemolytic anemia with established iron overload. This finding suggests that inhibition of this signaling pathway could be a novel and robust treatment strategy for several conditions that cause iron overload with anemia.
Materials and Methods
Animals and Treatments. Hif2α , and ODD-luc animals were described previously (25, 36, 40 mg of tamoxifen (Sigma) on 3 consecutive days. PhZ (Sigma) treatment was performed as previously described (27) . For BMT, mice received 12 Gy of total body irradiation split into two doses of 6 Gy in an interval of 4 h, and BMT was performed the day after irradiation. In vivo and ex vivo luminescence imaging was performed as previously described in 3-wk-old mice (40) . Tissue luciferase activity was quantitated by homogenizing the tissues in 1× passive lysis buffer, and 1 μL of extract was used for standard luciferase assay (Promega). CBC analysis was performed by the Unit for Laboratory Animal Medicine Pathology Core for Animal Research. The University Committee on the Use and Care of Animals at the University of Michigan approved all animal studies.
Western Blot. Membrane protein isolation was performed for the detection of DcytB and FPN1 as described previously (25) . Whole-cell extracts were isolated for the detection of DMT1, and nuclear extracts were isolated for the detection of HIF2α as previously described (24) . Antibodies against HIF2α (Novus Biologicals), GAPDH (Santa Cruz Biotechnology), Dmt1, DcytB, and Fpn1 (Alpha Diagnostic International), and Lamin B1 (Abcam) were used.
Iron Staining. Tissue-iron detection was performed in formalin fixed paraffinembedded sections stained with Perls' Prussian blue enhanced with DAB and H 2 O 2 with nuclear fast red counterstain.
Real-Time Quantitative PCR. RNA isolation, reverse transcription, real-time quantitative PCR (qPCR), and primers used for qPCR were described previously (27) .
Tissue-Iron Quantitation. Tissue nonheme iron was quantitated as previously described (53) . Briefly, tissues were homogenized in a 1-M HCl and 10% (wt/ vol) trichloroacetic acid solution and heated for 1 h at 95°C. Following a high-speed spin, iron was quantitated using a ferrozine solution and compared with a standard.
Statistics. Results are expressed as mean ± SD. P values were calculated by independent t test, 1-way ANOVA, and two-way ANOVA.
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